BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 9660980)

  • 1. Selection and characterization of beta-lactam-beta-lactamase inactivator-resistant mutants following PCR mutagenesis of the TEM-1 beta-lactamase gene.
    Vakulenko SB; Geryk B; Kotra LP; Mobashery S; Lerner SA
    Antimicrob Agents Chemother; 1998 Jul; 42(7):1542-8. PubMed ID: 9660980
    [TBL] [Abstract][Full Text] [Related]  

  • 2. X-ray structure of the Asn276Asp variant of the Escherichia coli TEM-1 beta-lactamase: direct observation of electrostatic modulation in resistance to inactivation by clavulanic acid.
    Swarén P; Golemi D; Cabantous S; Bulychev A; Maveyraud L; Mobashery S; Samama JP
    Biochemistry; 1999 Jul; 38(30):9570-6. PubMed ID: 10423234
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tazobactam is a potent inactivator of selected inhibitor-resistant class A beta-lactamases.
    Bonomo RA; Rudin SA; Shlaes DM
    FEMS Microbiol Lett; 1997 Mar; 148(1):59-62. PubMed ID: 9066111
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Aspartic acid for asparagine substitution at position 276 reduces susceptibility to mechanism-based inhibitors in SHV-1 and SHV-5 beta-lactamases.
    Giakkoupi P; Tzelepi E; Legakis NJ; Tzouvelekis LS
    J Antimicrob Chemother; 1999 Jan; 43(1):23-9. PubMed ID: 10381097
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Construction and characterization of mutants of the TEM-1 beta-lactamase containing amino acid substitutions associated with both extended-spectrum resistance and resistance to beta-lactamase inhibitors.
    Stapleton PD; Shannon KP; French GL
    Antimicrob Agents Chemother; 1999 Aug; 43(8):1881-7. PubMed ID: 10428907
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phenotypic study of resistance of beta-lactamase-inhibitor-resistant TEM enzymes which differ by naturally occurring variations and by site-directed substitution at Asp276.
    Caniça MM; Caroff N; Barthélémy M; Labia R; Krishnamoorthy R; Paul G; Dupret JM
    Antimicrob Agents Chemother; 1998 Jun; 42(6):1323-8. PubMed ID: 9624468
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Beta-lactamase patterns and betalactam/clavulanic acid resistance in Escherichia coli isolated from fecal samples from healthy volunteers.
    Gulay Z; Bicmen M; Amyes SG; Yulug N
    J Chemother; 2000 Jun; 12(3):208-15. PubMed ID: 10877515
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The role of a second-shell residue in modifying substrate and inhibitor interactions in the SHV beta-lactamase: a study of ambler position Asn276.
    Drawz SM; Bethel CR; Hujer KM; Hurless KN; Distler AM; Caselli E; Prati F; Bonomo RA
    Biochemistry; 2009 Jun; 48(21):4557-66. PubMed ID: 19351161
    [TBL] [Abstract][Full Text] [Related]  

  • 9. OHIO-1 beta-lactamase mutants: the Arg244Ser mutant and resistance to beta-lactams and beta-lactamase inhibitors.
    Lin S; Thomas M; Mark S; Anderson V; Bonomo RA
    Biochim Biophys Acta; 1999 Jun; 1432(1):125-36. PubMed ID: 10366735
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Overcoming resistance to beta-lactamase inhibitors: comparing sulbactam to novel inhibitors against clavulanate resistant SHV enzymes with substitutions at Ambler position 244.
    Thomson JM; Distler AM; Bonomo RA
    Biochemistry; 2007 Oct; 46(40):11361-8. PubMed ID: 17848099
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Class A beta-lactamases--enzyme-inhibitor interactions and resistance.
    Yang Y; Rasmussen BA; Shlaes DM
    Pharmacol Ther; 1999 Aug; 83(2):141-51. PubMed ID: 10511459
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Substitutions at position 105 in SHV family β-lactamases decrease catalytic efficiency and cause inhibitor resistance.
    Li M; Conklin BC; Taracila MA; Hutton RA; Skalweit MJ
    Antimicrob Agents Chemother; 2012 Nov; 56(11):5678-86. PubMed ID: 22908166
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ampicillin-sulbactam and amoxicillin-clavulanate susceptibility testing of Escherichia coli isolates with different beta-lactam resistance phenotypes.
    Oliver A; Pérez-Vázquez M; Martínez-Ferrer M; Baquero F; De Rafael L; Cantón R
    Antimicrob Agents Chemother; 1999 Apr; 43(4):862-7. PubMed ID: 10103192
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hyperproduction of inhibitor-susceptible TEM beta-lactamase is responsible for resistance of Serratia marcescens to beta-lactam-beta-lactamase inhibitor combinations.
    Zhao WH; Hu ZQ; Chen G; Ito R; Shimamura T
    Chemotherapy; 2008; 54(1):31-7. PubMed ID: 18063864
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Understanding resistance to beta-lactams and beta-lactamase inhibitors in the SHV beta-lactamase: lessons from the mutagenesis of SER-130.
    Helfand MS; Bethel CR; Hujer AM; Hujer KM; Anderson VE; Bonomo RA
    J Biol Chem; 2003 Dec; 278(52):52724-9. PubMed ID: 14534312
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Variants of β-lactamase KPC-2 that are resistant to inhibition by avibactam.
    Papp-Wallace KM; Winkler ML; Taracila MA; Bonomo RA
    Antimicrob Agents Chemother; 2015 Jul; 59(7):3710-7. PubMed ID: 25666153
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clavulanic acid inactivation of SHV-1 and the inhibitor-resistant S130G SHV-1 beta-lactamase. Insights into the mechanism of inhibition.
    Sulton D; Pagan-Rodriguez D; Zhou X; Liu Y; Hujer AM; Bethel CR; Helfand MS; Thomson JM; Anderson VE; Buynak JD; Ng LM; Bonomo RA
    J Biol Chem; 2005 Oct; 280(42):35528-36. PubMed ID: 15987690
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reversal of clavulanate resistance conferred by a Ser-244 mutant of TEM-1 beta-lactamase as a result of a second mutation (Arg to Ser at position 164) that enhances activity against ceftazidime.
    Imtiaz U; Manavathu EK; Mobashery S; Lerner SA
    Antimicrob Agents Chemother; 1994 May; 38(5):1134-9. PubMed ID: 8067751
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Substitution of Met-69 by Ala or Gly in TEM-1 beta-lactamase confer an increased susceptibility to clavulanic acid and other inhibitors.
    Madec S; Blin C; Krishnamoorthy R; Picard B; Chaibi el B; Fouchereau-Péron M; Labia R
    FEMS Microbiol Lett; 2002 May; 211(1):13-6. PubMed ID: 12052544
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical isolates of Escherichia coli producing multiple TEM mutants resistant to beta-lactamase inhibitors.
    Sirot D; Chanal C; Henquell C; Labia R; Sirot J; Cluzel R
    J Antimicrob Chemother; 1994 Jun; 33(6):1117-26. PubMed ID: 7928805
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.